JP2002536333A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002536333A5 JP2002536333A5 JP2000596939A JP2000596939A JP2002536333A5 JP 2002536333 A5 JP2002536333 A5 JP 2002536333A5 JP 2000596939 A JP2000596939 A JP 2000596939A JP 2000596939 A JP2000596939 A JP 2000596939A JP 2002536333 A5 JP2002536333 A5 JP 2002536333A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- levels
- pharmaceutically acceptable
- need
- oral formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 description 19
- 150000003839 salts Chemical class 0.000 description 10
- 238000009472 formulation Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 4
- 102000006991 Apolipoprotein B-100 Human genes 0.000 description 3
- 108010008150 Apolipoprotein B-100 Proteins 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- VDXAJPMEBTVBFW-UHFFFAOYSA-N 5,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)CCCC(O)(O)C=C VDXAJPMEBTVBFW-UHFFFAOYSA-N 0.000 description 1
- SFFYOOJRHFHVCM-LDCPCGJSSA-L calcium (3R,5S)-3,5-dihydroxyhept-6-enoate Chemical compound [Ca+2].O[C@@H](CC(=O)[O-])C[C@@H](C=C)O.O[C@@H](CC(=O)[O-])C[C@@H](C=C)O SFFYOOJRHFHVCM-LDCPCGJSSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9902590.0A GB9902590D0 (en) | 1999-02-06 | 1999-02-06 | Use of cholesterol-lowering agent |
| GB9902590.0 | 1999-02-06 | ||
| GBGB9921062.7A GB9921062D0 (en) | 1999-09-08 | 1999-09-08 | Use of cholestrol-lowering agent |
| GB9921062.7 | 1999-09-08 | ||
| PCT/GB2000/000285 WO2000045819A1 (en) | 1999-02-06 | 2000-02-01 | Use of cholesterol-lowering agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011035406A Division JP2011137023A (ja) | 1999-02-06 | 2011-02-22 | コレステロール低下薬の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002536333A JP2002536333A (ja) | 2002-10-29 |
| JP2002536333A5 true JP2002536333A5 (https=) | 2007-03-08 |
Family
ID=26315084
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000596939A Withdrawn JP2002536333A (ja) | 1999-02-06 | 2000-02-01 | コレステロール低下薬の使用 |
| JP2011035406A Pending JP2011137023A (ja) | 1999-02-06 | 2011-02-22 | コレステロール低下薬の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011035406A Pending JP2011137023A (ja) | 1999-02-06 | 2011-02-22 | コレステロール低下薬の使用 |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1150679A1 (https=) |
| JP (2) | JP2002536333A (https=) |
| KR (1) | KR100699287B1 (https=) |
| CN (1) | CN1347320A (https=) |
| AR (1) | AR022462A1 (https=) |
| AU (1) | AU769897B2 (https=) |
| BR (1) | BR0007991A (https=) |
| CA (1) | CA2358641A1 (https=) |
| CZ (1) | CZ20012631A3 (https=) |
| EE (1) | EE04659B1 (https=) |
| HK (1) | HK1040924A1 (https=) |
| HU (1) | HUP0105019A3 (https=) |
| ID (1) | ID30131A (https=) |
| IL (1) | IL144662A0 (https=) |
| IS (1) | IS5996A (https=) |
| MY (1) | MY136382A (https=) |
| NO (1) | NO319827B1 (https=) |
| NZ (1) | NZ512681A (https=) |
| PL (1) | PL349137A1 (https=) |
| SK (1) | SK11112001A3 (https=) |
| TR (1) | TR200102236T2 (https=) |
| WO (1) | WO2000045819A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
| SE0103509D0 (sv) * | 2001-10-19 | 2001-10-19 | Astrazeneca Ab | Rosuvastatin in pre demented states |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| WO2007142581A1 (en) * | 2006-06-07 | 2007-12-13 | Astrazeneca Ab | Combination product for the treatment or prevention of dyslipidaemia |
| CA2689523A1 (en) | 2007-06-20 | 2008-12-24 | Merck Sharp & Dohme Corp. | Cetp inhibitors derived from benzoxazole arylamides |
| EP2166847B1 (en) | 2007-06-20 | 2014-11-19 | Merck Sharp & Dohme Corp. | Cetp inhibitors derived from benzoxazole arylamides |
| WO2008156715A1 (en) | 2007-06-20 | 2008-12-24 | Merck & Co., Inc. | Cetp inhibitors derived from benzoxazole arylamides |
| EP2216095A1 (en) * | 2009-01-27 | 2010-08-11 | Koninklijke Philips Electronics N.V. | Microfluidic device for full blood count |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260446A (en) * | 1989-12-22 | 1993-11-09 | Basf Aktiengesellschaft | Aminothiazoles |
| JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
-
2000
- 2000-01-31 AR ARP000100408A patent/AR022462A1/es unknown
- 2000-02-01 HK HK02102713.0A patent/HK1040924A1/zh unknown
- 2000-02-01 TR TR2001/02236T patent/TR200102236T2/xx unknown
- 2000-02-01 AU AU23051/00A patent/AU769897B2/en not_active Revoked
- 2000-02-01 PL PL00349137A patent/PL349137A1/xx not_active Application Discontinuation
- 2000-02-01 BR BR0007991-0A patent/BR0007991A/pt not_active Application Discontinuation
- 2000-02-01 CZ CZ20012631A patent/CZ20012631A3/cs unknown
- 2000-02-01 HU HU0105019A patent/HUP0105019A3/hu unknown
- 2000-02-01 EP EP00901748A patent/EP1150679A1/en not_active Withdrawn
- 2000-02-01 ID IDW00200101666A patent/ID30131A/id unknown
- 2000-02-01 KR KR1020017009822A patent/KR100699287B1/ko not_active Ceased
- 2000-02-01 IL IL14466200A patent/IL144662A0/xx unknown
- 2000-02-01 EE EEP200100404A patent/EE04659B1/xx not_active IP Right Cessation
- 2000-02-01 JP JP2000596939A patent/JP2002536333A/ja not_active Withdrawn
- 2000-02-01 WO PCT/GB2000/000285 patent/WO2000045819A1/en not_active Ceased
- 2000-02-01 CN CN00803519A patent/CN1347320A/zh active Pending
- 2000-02-01 SK SK1111-2001A patent/SK11112001A3/sk not_active Application Discontinuation
- 2000-02-01 NZ NZ512681A patent/NZ512681A/en not_active IP Right Cessation
- 2000-02-01 CA CA002358641A patent/CA2358641A1/en not_active Abandoned
- 2000-02-04 MY MYPI20000415A patent/MY136382A/en unknown
-
2001
- 2001-07-10 IS IS5996A patent/IS5996A/is unknown
- 2001-08-03 NO NO20013810A patent/NO319827B1/no active IP Right Review Request
-
2011
- 2011-02-22 JP JP2011035406A patent/JP2011137023A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004522714A5 (https=) | ||
| JP2009514874A5 (https=) | ||
| CA2429979A1 (en) | Treatment of statin side effects | |
| RU2003114300A (ru) | Применение розувастатина (zd-4522) в лечении гетерозиготной семейной гиперхолестеринемии | |
| JP2004512328A5 (https=) | ||
| DK1227806T3 (da) | Farmaceutisk præparat indeholdende tolterodin og dets anvendelse | |
| ATE424810T1 (de) | Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung | |
| CA2608024A1 (en) | Use of flibanserin in the treatment of chronic pain | |
| JP2006516272A5 (https=) | ||
| IL158668A0 (en) | Deuterated 3-piperidinopropiophenone and medicaments containing said compounds | |
| EP2359826B1 (en) | Combination of HMG-COA reductase inhibitor rosuvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-N-oxide for the treatment of inflammatory pulmonary diseases | |
| WO1993009768A1 (fr) | Fomentation contenant du cetorolac | |
| JP2002528502A5 (https=) | ||
| JP2002536333A5 (https=) | ||
| JP2010065060A (ja) | 心不全処置のための複合治療 | |
| JP2016512234A (ja) | 薬学的複合製剤 | |
| CN101795684A (zh) | 他汀类化合物与抗肥胖药的组合 | |
| ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
| RU2001133458A (ru) | Производные 4-фенилпиримидина | |
| HK1040924A1 (zh) | 降膽固醇劑的應用 | |
| JP2004515526A (ja) | ロキソプロフェン含有筋肉注射用医薬組成物 | |
| RU2004112422A (ru) | Роувастатин в преддеменционных состояниях | |
| CA2480275A1 (en) | Statin therapy for enhancing cognitive maintenance | |
| JP2005525391A5 (https=) | ||
| JP2004533434A5 (https=) |